Tianjin Med J ›› 2017, Vol. 45 ›› Issue (12): 1333-1336.doi: 10.11958/20170724
Previous Articles Next Articles
MIAO Ya-jing1, JIN Fang2, XU Peng-yu2, QIU Xiao-fei2△
Received:
Revised:
Published:
Online:
MIAO Ya-jing1, JIN Fang2, XU Peng-yu2, QIU Xiao-fei2△. Research progress of IL-8 in lung cancer[J]. Tianjin Med J, 2017, 45(12): 1333-1336.
Abstract: Lung cancer is the leading cause of cancer-related deaths worldwide. Acquired drug resistance and metastasis are the main causes of treatment failure in lung cancer. Tumor microenvironment is a complex network for the survival and progression of tumor cells, in which inflammatory factors play a critical role in drug resistance and metastasis. Interleukin (IL)-8 is one of critical pro-inflammatory cytokines responsible for cell proliferation, invasion and metastasis, drug resistance and early recurrence in lung cancer. A serum based approach is advantageous for providing a real-time detection and evaluation of disease status in patients. In this review, we summarize the recent advances of IL-8 in predicting prognosis and radiation-induced lung toxicity (RILT), as well as increasing resistance and stem-like characteristics of lung cancer.
Key words: lung neoplasms, interleukin-8, cancer stem cells, prognosis, review
/ Recommend
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.tjyybjb.ac.cn/EN/10.11958/20170724
https://www.tjyybjb.ac.cn/EN/Y2017/V45/I12/1333